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Reply to Ogino and Wilson
To the Editor:
Drs. Ogino and Wilson (2002 [in this issue]) raised some
issues regarding our paper on quantitative testing of
SMN1 and SMN2 in spinal muscular atrophy (SMA)
(Feldko¨tter et al. 2002). First, they raised some ethical
issues regarding the testing of unaffected children for
SMA. We are also aware of the controversial aspects of
such testing and, in general, agree with Drs. Ogino and
Wilson: the identification, at birth, of homozygous ab-
sence of SMN1 in children, followed by the quantitative
analysis of SMN2, should be offered as a prognostic tool
only when a therapy for SMA is available. In this case,
a newborn screening (similar to that in phenylketonuria)
could—and possibly should—be considered. Since sev-
eral drugs that up-regulate full-length SMN2 have been
found (Andreassi et al. 2001; Chang et al. 2001) and
since the identification of many more is in progress, the
development of a therapy for SMA seems likely to be-
come a reality in the near future. Therefore, the devel-
opment of a highly sensitive and fast method to deter-
mine the number of SMN2 copies will be an essential
prerequisite before starting a therapy. Furthermore, the
identification, immediately after birth, of children who
carry homozygous absence of SMN1 will be equally es-
sential, to start the therapy before the motor neurons
are degenerated. On the basis of the number of SMN2
copies, the dosage and starting-point of a therapy may
significantly vary.
Since an efficient therapy has to be started early, we
calculated the posterior probability that a child with an
SMN1 deletion would develop type I, type II, or type III
SMA, under the assumption that the analysis is done
immediately after birth. As a consequence, we have used
a Bayesian-type analysis that is based on the odds ratios
and a priori probabilities as chosen.
We reevaluated the sensitivity calculations, and we
agree with Drs. Ogino and Wilson that the sensitivity
of the test, for the detection of an SMA carrier from the
general population without family history, is 95.9% (i.e.,
), since 2.4% of carriers have two1 [0.024 0.017]
SMN1 copies per chromosome and 1.7% carry intra-
genic SMN1 mutations. Therefore, there is a posterior
probability of ∼1:850 (i.e., ) that a[4.1/100] # [1/35]
person from the general population who carries two
SMN1 copies is an SMA carrier. The carrier frequency
of 1:35 is based on the results presented in our previous
article (Feldko¨tter et al. 2002). The sensitivity of the test
for the detection of an SMA carrier from a family with
an affected patient who carries a homozygous absence
of SMN1 is 97.6% (i.e., ).1 0.024
With reference to the primers designed to detect either
SMN1 or SMN2, the test is based on two nucleotide
differences in exon 7 and in intron 7 (position 100).
This implies that converted SMN genes may amplify
with a decreased efficiency. At this point, it is important
to mention that, in the large majority (42/44 [∼95%])
of converted SMN genes, the complete gene, except for
the region containing the nucleotide difference in exon
8, is converted (Hahnen et al. 1996). This means that,
for most converted SMN genes, the two primers that we
have applied lie in either SMN1 or SMN2 only and will
not hamper the efficiency of the PCR. Additionally, the
analysis of 20 patients with only homozygous absence
of SMN1 exon 7 showed identical number of SMN2
copies analyzed with both methods—multiplex com-
petitive PCR (Wirth et al. 1999) and LightCycler PCR
(Feldko¨tter et al. 2002). Nevertheless, the efficiency of
the PCR may be reduced for those rarely observed SMN
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Figure 1 Path diagram showing the relationship between two
observed variables ( and ) for a pair of siblings. Covariation be-V V1 2
tween the phenotypes is due to the QTL (Q), genetic and environmental
sources that are shared among siblings ( and ), and nonsharedS S1 2
sources of variation ( and ).E E1 2
genes in which the breakpoint lies between the two prim-
ers used in the LightCycler PCR.
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The Power of Multivariate Quantitative-Trait Loci
Linkage Analysis Is Influenced by the Correlation
between Variables
To the Editor:
In a recent article, Sham et al. (2000) investigated the
power of variance-components linkage analysis by deriv-
ing an analytic expression for the noncentrality parame-
ter (NCP) of the linkage test. The authors demonstrated
that the NCP—and, hence, the power of the test to detect
linkage—was determined primarily by the square of the
additive and dominance genetic components of variance
due to the quantitative-trait locus (QTL) and by the re-
sidual correlation between siblings. However, Sham et al.
presented calculations for the univariate case only. Re-
cently, it has been demonstrated that the power of QTL
linkage analysis may be increased by use of multivariate
techniques that analyze the pleiotropic action of the QTL
on several variables (Boomsma 1996; Martin et al. 1997).
In particular, the power of multivariate linkage analy-
sis is strongly influenced by the correlation between the
variables, being greatest when the QTL induces covar-
iation between the variables in the direction opposite to
the residual correlation (Allison et al. 1998; Amos et al.
2001). Here, I follow the methodology of Sham et al., to
demonstrate analytically, for the first time, how the power
of a bivariate variance-components linkage analysis de-
pends not only on the magnitude and direction of the
correlation between variables but also on the source of
this correlation.
The relationship between two observable variables is
parameterized in terms of the path model displayed in
figure 1. Observed variables for each sib pair (square
boxes) are due to the combined action of several latent
variables (circles), including a pleiotropic QTL (Q), poly-
